ADT	androgen deprivation therapy;
AML	acute myeloid leukemia;
AKT/PKB	protein kinase B;
AR	androgen receptor;
ARE	androgen response element;
ASK1	apoptosis signal-regulating kinase;
BAT	bipolar androgen therapy;
CRPCa	castration-resistant prostate cancer;
CSPCa	castration-sensitive prostate cancer;
DAB2IP	disabled homolog 2-interacting protein;
HSP	heat shock protein;
LBD	ligand binding domain;
MEFs	mouse embryonic fibroblasts;
mTOR	mammalian target of Rapamycin;
mTORC1/2	mTOR complex 1/2;
PCa	prostate cancer;
PDK1	phosphoinositide-dependent kinase 1;
PH	pleckstrin homology;
PI3K	phosphatidylinositol-3-kinase;
PI(4,5)P2	phosphatidylinositol-4,5-biphosphate
PI(3,4)P2	phosphatidylinositol-3,4-biphosphate
PIP3	phosphatidylinositol-3,4,5-triphosphate
PSA	prostate-specific antigen;
RTK	receptor tyrosine kinase;
p70S6K	p70S6 kinase;
SAL	supraphysiological androgen level;
SHIP1/2	Src homology 2 domain containing inositol polyphosphate 5-phosphatase 1/2